Citius Oncology (CTOR) Price & Analysis

Compare

115 Followers

CTOR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.55 - $6.19

Previous CloseN/A

Volume120.49K

Average Volume (3M)204.77K

Market Cap

$153.66M

Enterprise Value$315.05M

Total Cash (Recent Filing)$112.00

Total Debt (Recent Filing)$3.80M

Price to Earnings (P/E)16.7

Beta0.18

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.27

Shares Outstanding83,513,440

10 Day Avg. Volume169,743

30 Day Avg. Volume204,770

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)2.16

Price to Sales (P/S)0.00

P/FCF Ratio-20.41

Enterprise Value/Market Cap2.05

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.36

Forecast

1Y Price Target

$6.00

Price Target Upside227.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Commercial StrategyCitius has completed commercial-scale manufacturing and entered into distribution partnerships, ensuring launch supply for 12–18 months and securing commercial supply agreements.

Partnerships And Market ExpansionCitius Oncology announced entry into an exclusive agreement with Integris Pharma S.A. to bring Lymphir to market in Southern European countries, providing an opportunity to generate revenue and build awareness.

Bears Say

Capital NeedsWhile the company will likely need additional capital in the near term, the recent funding alleviates some of the pressure and allows support for launching Lymphir.

Citius Oncology News

Citius Oncology signs distribution agreement for Lymphir in Southern Europe

Citius Oncology (CTOR)is engaging with regional distribution partners to make Lymphir available to eligible patients through country-specific Named...

4d ago

CTOR

Maxim upgrades Citius Oncology to Buy, sees its capital needs being met

Maxim upgraded Citius Oncology (CTOR) to Buy from Hold with a $6 price target The company has taken...

18d ago

CTOR

Citius Oncology upgraded to Buy from Hold at Maxim

Maxim analyst Michael Okunewitch upgraded Citius Oncology (CTOR) to Buy from Hold with a $6 price target Published...

18d ago

CTOR

Citius Oncology’s Strategic Expansion and Market Positioning Drive Buy Rating

Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Oncology and keeping the price target...

3d ago

CTOR

Citius Oncology Issues Warrants in Private Placement

Citius Oncology ( ($CTOR) ) has provided an announcement. On September 19, 2025, Citius Oncology, Inc. issued warrants...

21d ago

CTOR

Citius Oncology Raises $7.48M in Direct Offering

Citius Oncology ( ($CTOR) ) has issued an announcement. On September 9, 2025, Citius Oncology entered into agreements...

1M ago

CTOR

Citius Oncology announces pricing of $9M registered direct offering

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into a securities...

1M ago

CTOR

CTXR

Citius Oncology files $200M mixed securities shelf

08:03 EDT Citius Oncology (CTOR)files $200M mixed securities shelf Published first on TheFly – the ultimate source for...

1M ago

CTOR

Citius Oncology Conducts Public Offering of Stock

The latest announcement is out from Citius Oncology ( ($CTOR) ). On July 17, 2025, Citius Oncology, Inc....

2M ago

CTOR

Citius Oncology Completes $9M Public Offering

Citius Oncology ( ($CTOR) ) has provided an announcement. On July 16, 2025, Citius Oncology, Inc. announced the...

3M ago

CTOR

Citius Oncology signs distribution agreement for Lymphir with Cencora

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), executed a distribution services agreement with Cencora –...

3M ago

CTOR

CTXR

Citius Oncology files to sell $15M of common stock, warrants

Maxim Group is acting as exclusive placement agent. Published first on TheFly – the ultimate source for real-time,...

3M ago

CTOR

Citius Oncology Regains Nasdaq Compliance June 2025

Citius Oncology ( ($CTOR) ) has issued an update. On June 26, 2025, Citius Oncology, Inc. announced that...

4M ago

CTOR

Citius Oncology Prepares for LYMPHIR™ Launch

Citius Oncology ( ($CTOR) ) just unveiled an announcement. On June 17, 2025, Citius Oncology announced that preparations...

4M ago

CTOR

CTOR FAQ

What was Citius Oncology’s price range in the past 12 months?

Citius Oncology lowest stock price was $0.55 and its highest was $6.19 in the past 12 months.

What is Citius Oncology’s market cap?

Citius Oncology’s market cap is $153.66M.

When is Citius Oncology’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Citius Oncology’s earnings last quarter?

Citius Oncology released its earnings results on May 14, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.02.

Is Citius Oncology overvalued?

According to Wall Street analysts Citius Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Citius Oncology pay dividends?

Citius Oncology does not currently pay dividends.

What is Citius Oncology’s EPS estimate?

Citius Oncology’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Citius Oncology have?

Citius Oncology has 83,513,440 shares outstanding.

What happened to Citius Oncology’s price movement after its last earnings report?

Citius Oncology reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 5.917%.

Which hedge fund is a major shareholder of Citius Oncology?

Currently, no hedge funds are holding shares in CTOR

Citius Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.78%

Trailing 12-Months

Asset Growth

85.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Citius Oncology

Citius Oncology (CTOR) is a pharmaceutical company operating within the biotechnology and healthcare sectors. The company focuses on the development and commercialization of innovative therapies aimed at treating cancer. Its core products include a pipeline of experimental cancer drugs designed to target various oncological indications, leveraging advanced research and development techniques to improve patient outcomes.

Citius Oncology (CTOR) Earnings & Revenues

Historic Earnings Reports

CTOR Stock 12 Month Forecast

Average Price Target

$6.00

▲(227.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","-1":"-$1","2.25":"$2.25","5.5":"$5.5","8.75":"$8.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.25,5.5,8.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.28,2.59,2.9,3.21,3.52,3.83,4.14,4.45,4.76,5.07,5.38,5.6899999999999995,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.28,2.59,2.9,3.21,3.52,3.83,4.14,4.45,4.76,5.07,5.38,5.6899999999999995,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.28,2.59,2.9,3.21,3.52,3.83,4.14,4.45,4.76,5.07,5.38,5.6899999999999995,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.35,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.39,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.77,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.35,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.89,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >